Therapeutic Strategies for Diabetes: Immune Modulation in Pancreatic β Cells

Jo, Sugyeong; Fang, Sungsoon

doi:10.3389/fendo.2021.716692

Cited by 13 publications

(11 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Immunomodulating Moleculesmentioning

confidence: 99%

“…Microbiota-derived molecules have also been used in immunomodulation, and they will be briefly described here [ 110 ]. Increasingly, type I and type II diabetes are linked to intrinsic changes in gut microbiota, which may release smaller quantities of short-chain fatty acids, such as butyrate [ 110 , 111 ]. Diminished butyrate conversion from lactate has been correlated with reduced regulatory T cell generation and a weakened suppression of the autoimmune system [ 112 ].…”

Section: Immunomodulating Moleculesmentioning

confidence: 99%

See 1 more Smart Citation

Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications

et al. 2022

View full text Add to dashboard Cite

Non-targeted persistent immune activation or suppression by different drug delivery platforms can cause adverse and chronic physiological effects including cancer and arthritis. Therefore, non-toxic materials that do not trigger an immunogenic response during delivery are crucial for safe and effective in vivo treatment. Hydrogels are excellent candidates that can be engineered to control immune responses by modulating biomolecule release/adsorption, improving regeneration of lymphoid tissues, and enhancing function during antigen presentation. This review discusses the aspects of hydrogel-based systems used as drug delivery platforms for various diseases. A detailed investigation on different immunomodulation strategies for various delivery options and deliberate upon the outlook of such drug delivery platforms are conducted.

show abstract

Section: Immunomodulating Moleculesmentioning

confidence: 99%

Section: Immunomodulating Moleculesmentioning

confidence: 99%

Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Fecal microbiota transplantation (FMT), also called stool/fecal transplantation or fecal bacterio therapy, is the fermentation or engraftment of liquescent filtrate feces from a healthy donor into the gut of a receiver to treatment a selected disease. [10] FMT can be administered through a GIT with the help of endoscopy, a nanosized enteric tubes, and capsules for incorporation. The supposed mechanism of this method is the replacement of microbiota community of gut which recreates the traditional gut function.…”

Section: Fmtmentioning

confidence: 99%

Untitled

2022

AJP

View full text Add to dashboard Cite

In current scenario, the investigational studies in pathology fields focus on those microbiotas which can produce sever disorders and also terminate the microbiota colonies that cause or which altered and arise with some diseasecausing agents. Fecal microbiota transplantation (FMT) may alter the acceptors gut microbiota and maintain the composition in normal range, which helps to give beneficial pharmacological effects in gastrointestinal tract (GIT) related disease as well as, extra-GIT disorders. Alteration in microbiomes have given appropriate clinical perceptions in both gut and oral disorders. FMT re-established miscellaneous bacterial profile to GIT. The study was focused on the evaluation of efficacy of this method to treat various infections arises with Clostridium difficile bacteria. From the various studies, it may be hypothesized that the FMT reflects that it has potency to treat the C. difficile infections and achieved success rate in between 80 and 100%. Fecal microbiota can be transplant by both either antegrade or retrograde routes. The history of FMT belongs to the 4 th century and comes in enforcement in 2013 after approving by the USFDA.

show abstract

“…Several reviews on the role of inflammation during β-cell dysfunction in T2D have been conducted. For example, Jo and Fang[ 10 ] reviewed evidence indicating that malfunctioning of the essential components of the inflammation, including helper T cells, cytotoxic T cells, and regulatory T cells may underpin pancreatic β cell failure in T2D. Sun et al [ 11 ] recently discussed that aberrant epigenetic signatures, including DNA methylation, chromatin accessibility, histone alteration, and non-coding RNAs orchestrate β-cell malfunction during embryonic growth and postnatal development, thus contributing to β cell dysfunction.…”

Section: Introductionmentioning

confidence: 99%

Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress

Dludla¹,

Mabhida²,

Ziqubu³

et al. 2023

World J Diabetes

View full text Add to dashboard Cite

Insulin resistance and pancreatic β-cell dysfunction are major pathological mechanisms implicated in the development and progression of type 2 diabetes (T2D). Beyond the detrimental effects of insulin resistance, inflammation and oxidative stress have emerged as critical features of T2D that define β-cell dysfunction. Predominant markers of inflammation such as C-reactive protein, tumor necrosis factor alpha, and interleukin-1β are consistently associated with β-cell failure in preclinical models and in people with T2D. Similarly, important markers of oxidative stress, such as increased reactive oxygen species and depleted intracellular antioxidants, are consistent with pancreatic β-cell damage in conditions of T2D. Such effects illustrate a pathological relationship between an abnormal inflammatory response and generation of oxidative stress during the progression of T2D. The current review explores preclinical and clinical research on the patho-logical implications of inflammation and oxidative stress during the development of β-cell dysfunction in T2D. Moreover, important molecular mechanisms and relevant biomarkers involved in this process are discussed to divulge a pathological link between inflammation and oxidative stress during β-cell failure in T2D. Underpinning the clinical relevance of the review, a systematic analysis of evidence from randomized controlled trials is covered, on the potential therapeutic effects of some commonly used antidiabetic agents in modulating inflammatory makers to improve β-cell function.

show abstract

Therapeutic Strategies for Diabetes: Immune Modulation in Pancreatic β Cells

Cited by 13 publications

References 142 publications

Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications

Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications

Untitled

Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress

Contact Info

Product

Resources

About